ACCESS Newswire

Pressure BioSciences Inc.

21.7.2021 15:27:15 CEST | ACCESS Newswire | Press release

Share
Pressure BioSciences Announces Major Business Expansion, Establishing Eco-Friendly Agrochemicals Subsidiary and Initiating Plans to Drive Accretive 2021 Revenue

Significant Order for Environmentally Friendly Agrochemical Material Placed to Fulfill Initial Demand;
Subsidiary will House Announced Asset Acquisition from Global Agrochemicals Innovator

SOUTH EASTON, MA / ACCESSWIRE / July 21, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced it has established a wholly-owned agrochemicals subsidiary named PBI Agrochem, Inc. The Company further announced that it has purchased over a half-million dollars of specialized, proprietary material to be used to fulfill initial demand for its eco-friendly and effective agrochemical pest control and growth stimulant products. Finally, the Company remains focused on its ongoing efforts and is optimistic that it will complete the previously announced asset acquisition of a global developer and supplier of environmentally responsible and organically natural agrochemicals in the coming weeks, subject to certain conditions, including the completion of all due diligence and acquisition financing.

Global population growth is driving a significant increase in food production demand, which in turn is driving an increased need for the use of pesticides and fertilizers. Whether from traditional production-boosting synthetics or the new generation of eco-friendly agrochemicals, all pesticides and fertilizers face common challenges in getting oily "active ingredients" (the material that is going to exert desired effects on the plant or the pest) to become effectively absorbed, which is required for optimal bioavailability (or efficacy) within the targeted plant species. Pesticides, used to control insects that damage crops and severely limit production, are projected to grow in worldwide sales from $84.5 billion in 2019 to $131 billion by 2023. Fertilizers, used to replenish soil with essential nutrients required for better crop growth and production, are expected to achieve global sales of approximately $232 billion by 2025.

PBI's Ultra Shear Technology™ ("UST™") nanoemulsification platform was specifically designed to make oils effectively soluble in water. Consequently, UST is expected to enable safer and more environmentally responsible and effective agrochemical dosing while reducing the amount and consequently the cost burden of expensive active ingredients required in agrochemical product formulations.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Our breakthrough UST platform for processing high value oil-based active ingredients into superior quality nanoemulsions is expected to significantly improve absorption and bioavailability of active oily ingredients, with safer, better controlled, and more economical dosing delivery to the targeted plants. We believe our eco-friendly agrochemical products - some to be enhanced by UST processing - will offer revolutionary changes in product capabilities and innovation to agriculture customers worldwide."

Mr. John B. Hollister, Director of Sales and Marketing at PBI, said: "We have developed a very aggressive yet realistic plan to expand our business into the eco-friendly agrochemical space, which is currently over-flowing with growth opportunities. We believe few areas are hotter than eco-friendly agrochemicals, especially those that have been designed to minimize the long-term global environmental impact of persistent or glacially-slow degrading traditional agrochemicals."

Mr. Hollister added: "We look forward with anticipation to the close of the asset acquisition. We believe the line of high quality, eco-friendly agrochemical products being acquired, when combined with PBI's technical capabilities and innovative technology platforms, will result in strong product sales with significant revenue from the new agrochemical business sector for PBIO, beginning as soon as this current third quarter of 2021."

PBI's Board Chairman, Mr. Jeffrey N. Peterson provided a broader context: "In addition to our goal of finishing FY2021 with record strong revenue and a significant decrease in operating loss, we are also intently focused on two additional objectives: (i) eliminating from our balance sheet the expensive debt that PBI has necessarily utilized over the past few years to manage through periods when more reasonable equity financing was unavailable, and (ii) up-listing to either NASDAQ or the NYSE at the earliest appropriate opportunity. We are making excellent progress on both fronts and look forward to updating PBI's shareholders regularly on these two very important goals."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, youcan identify forward-looking statements by terminology such as "may," "will," "should,""could,""would," "expects," "plans," "intends,""anticipates," "believes," estimates,""predicts," "projects,""potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not placeundue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially fromany forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com.
Please visit us on Facebook, LinkedIn, and Twitter.

PRESS CONTACTS:

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (508) 230 -1828 (T)
Jeffrey N. Peterson, Chairman (650) 703-8557(T)

SOURCE: Pressure BioSciences, Inc.



View source version on accesswire.com:
https://www.accesswire.com/656448/Pressure-BioSciences-Announces-Major-Business-Expansion-Establishing-Eco-Friendly-Agrochemicals-Subsidiary-and-Initiating-Plans-to-Drive-Accretive-2021-Revenue

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

LiberNovo 2026 Triple Launch: SE, Pro, and Maxis Introduce Dynamic Ergonomics for Every Body Type Across Europe18.5.2026 19:00:00 CEST | Press release

LONDON, GB / ACCESS Newswire / May 18, 2026 / LiberNovo, the premium ergonomic chair brand pioneering movement-based seating, today confirmed the full details of its 2026 product expansion for the European market. Three new lines-the Omni SE, Omni Pro, and the all-new Maxis series-will be available to customers across the UK and EU starting June 16, with pre-orders now open. Across Europe, the shift toward hybrid and remote work has turned the home office into a permanent fixture. Yet the chair at the centre of that setup is often the last thing to be upgraded. Most ergonomic seating still operates on a decades-old premise: find the correct posture, lock it in, stay put. LiberNovo rejects that model entirely. Its Dynamic Ergonomics platform is built around continuous adaptation-chairs that respond to how users actually move through their day, rather than forcing them into a fixed position. With three distinct product lines, that approach now reaches users of every build and budget. Omn

Europe's Healthcare IT Market Enters the 2027 Readiness Cycle as Black Book Names 26 Top Client-Rated Vendors During HIMSS26 Week in Copenhagen18.5.2026 18:00:00 CEST | Press release

Category-specific honors identify client-rated leaders in data-ready EHRs, interoperability, enterprise imaging, cloud, cybersecurity, AI, advisory, analytics, clinical decision support and digital health infrastructure COPENHAGEN, DK / ACCESS Newswire / May 18, 2026 / Black Book Research today announced its 2026 European Healthcare IT Client Satisfaction Honors, recognizing 26 healthcare technology vendors and platforms whose strongest client-facing performance aligns with the next phase of European digital health: trusted data, cross-border interoperability, AI accountability, cybersecurity resilience, cloud modernization, enterprise imaging liquidity, analytics readiness and clinical workflow transformation. The announcement is timed to HIMSS26 Europe, taking place 19-21 May 2026 at the Bella Center in Copenhagen, Denmark, where healthcare leaders, innovators and policymakers are convening around digital maturity, AI, interoperability, cybersecurity and health system transformation.

Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization18.5.2026 14:37:00 CEST | Press release

Forbes' Third Highest-Paid Athlete in the World Brings Global Platform to Datavault AI's Sports Illustrated Exchange and NIL Monetization Initiative PHILADELPHIA, PA / ACCESS Newswire / May 18, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today announced that two-time world heavyweight champion Tyson Fury has signed on as International Spokesperson for Datavault AI a deal brokered by Nick Hunter of P11. Ranked No. 3 on Forbes' 2025 list of the world's highest-paid athletes with $146 million in estimated earnings (Forbes 2025), Fury brings global star power, and a uniquely personal understanding of what it means to own, protect, and capitalize on a name, to Datavault AI's mission of empowering individuals and organizations to monetize their data and digital assets. Known worldwide as "The Gypsy King," his appointment immediately precede

Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform15.5.2026 22:55:00 CEST | Press release

NESHER, ISRAEL / ACCESS Newswire / May 15, 2026 / Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments. As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines. Originally developed in collaboration with leading anti-drone technology companies, the solution has already been prov

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program14.5.2026 21:05:00 CEST | Press release

Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination Proposed transaction valued at approximately $15 million Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye